Harbour BioMed said China’s NMPA has approved its IND application for HBM7004, a novel bispecific antibody candidate for advanced solid tumors. While this is an early regulatory milestone rather than efficacy data, IND clearance reduces development friction and supports the company’s clinical pipeline progression.
Harbour BioMed said China’s NMPA has approved its IND application for HBM7004, a novel bispecific antibody candidate for advanced solid tumors. While this is an early regulatory milestone rather than efficacy data, IND clearance reduces development friction and supports the company’s clinical pipeline progression.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
